

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes: results from the Brazilian COVID-19 Registry

Authors:

Israel Molina PhD^{1*} (Romero IM - israel.molina@fiocruz.br, 0000-0001-6642-7515)

Milena S. Marcolino PhD^{2*} (Marcolino MS - milenamarc@ufmg.br, 0000-0003-4278-3771)

Magda C. Pires PhD^{3*} (Pires MC – magda@est.ufmg.br, 0000-0003-3312-4002)

Lucas Emanuel F. Ramos⁴ (Ramos LEF - luckermos19@gmail.com, 0000-0001-7844-0581)

Rafael T. Silva⁴ (Silva RT - rafaelsilva@posteo.net, 0000-0002-9270-5328)

Milton H. Guimarães Júnior MSc⁵ (Guimarães Júnior MH - miltonhenriques@yahoo.com.br, 0000-0002-2127-8015)

Isaias José R. de Oliveira MSc⁶ (Oliveira IJR - isaias.ramos@gmail.com, 0000-0001-9232-4309)

Rafael L.R. Carvalho PhD⁷ (Carvalho RLR - rafaelsjdr@hotmail.com, 0000-0003-3576-3748)

Aline Gabrielle S. Nunes⁸ (Nunes AGS - alinegsn89@yahoo.com.br, 0000-0001-8036-0871)

Ana Lara R. M. de Barros⁹ (Barros ALRM - barrosanalara@gmail.com, 0000-0002-2612-4744)

Ana Luiza B. A. Scotton¹⁰ (Scotton ALBA - analuiza.bahia@yahoo.com.br, 0000-0002-5857-2031)

Angélica Aparecida C. Madureira⁹ (Madureira AAC - angelicaacmadureira@gmail.com, 0000-0002-8465-5674)

Bárbara L. Farace¹¹ (Farace BL - barbarafarace@gmail.com, 0000-0002-6172-1093)

Cíntia A. de Carvalho¹² (Carvalho CA - carvalho.cintiaa@gmail.com, 0000-0001-8240-2481)

Fernanda D. A Rodrigues PhD¹³ (Rodrigues DA - fe.athayde@gmail.com, 0000-0001-7368-3592)

Fernando Anschau PhD¹⁴ (Anschau F - afernando@ghc.com.br, 0000-0002-2657-5406)

Fernando A. Botoni¹⁵ (Botoni FA - fbotoni@medicina.ufmg.br, 0000-0001-6268-8507)

Guilherme F. Nascimento MSc¹⁶ (Nascimento GF - guilhermefagundesn@hotmail.com, 0000-0001-9064-7067)

Helena Duani PhD¹⁷ (Duani H - hduani@yahoo.com.br, 0000-0001-9345-018X)
Henrique C. Guimarães PhD¹⁸ (Guimarães HC - hcerqueirag@gmail.com, 0000-0001-6511-7400)
Joice C. de Alvarenga¹² (Alvarenga JC - joice-alvarenga@hotmail.com, 0000-0003-3536-7112)
Leila B. Moreira¹⁹ (Moreira LB - lbmoreira@hcpa.edu.br, 0000-0002-4730-7988)
Liege B. Zandoná²⁰ (Zandoná LB - liegezandona@hotmail.com, 0000-0001-6697-6426)
Luana F. de Almeida²¹ (Almeida LF - luana.fonseca.almeida@gmail.com, 0000-0001-6934-298X)
Luana M. Oliveira MSc²² (Oliveira LM - luanalmo19.09@gmail.com, 0000-0003-4639-4546)
Luciane Kopittke PhD²³ (Kopittke L - kluciane@ghc.com.br, 0000-0002-6606-7756)
Luís C. Castro PhD²⁴ (Castro LC - pharmlucamsc@gmail.com, 0000-0003-2379-0167)
Luisa Elem A. Santos²⁵ (Santos LEA, luisa_elem@hotmail.com, 0000-0003-0264-5497)
Máderson A. S. Cabral MD²⁶ (Cabral MAS - madersonalvares@hotmail.com, 0000-0001-8556-1998)
Maria Angélica P. Ferreira PhD¹⁹ (Ferreira MAP - mpiferreira@hcpa.edu.br, 0000-0003-0961-524X)
Natália C. S. Sampaio²⁷ (Sampaio NCS - natsamster@gmail.com, 0000-0002-5799-8006)
Neimy R. de Oliveira²⁷ (Oliveira NR - neimyramos@gmail.com, 0000-0001-5408-9459)
Saionara C. Francisco MSc²⁸ (Francisco SC - saionaracf@gmail.com, 0000-0002-9655-6294)
Sofia J. T. S. Lopes²⁹ (Lopes SJTS - sofiajarjour@gmail.com, 0000-0002-5010-2916)
Tatiani O. Fereguetti³⁰ (Fereguetti TO - tatianifereguetti@gmail.com, 0000-0001-5845-0715)
Veridiana B. dos Santos³¹ (Santos VB - veridbaldon@hotmail.com, 0000-0002-9372-5785)
Victor Eliel B. de Carvalho²⁹ (Carvalho VEB - perillo.victor@gmail.com, 0000-0002-9495-6112)
Yuri C. Ramires³² (Ramires YC - yuri.ramires@gmail.com, 0000-0002-0730-8716)

Antonio Luiz P. Ribeiro PhD³³ (Ribeiro ALP - tom@hc.ufmg.br, 0000-0002-2740-0042)

Freddy Antonio B. Moscoso³⁴ (Moscoso FAB - cardio.britom@gmail.com, 0000-0002-4141-7780)

Rogério Moura³⁵ (Moura R - professor@cursointensivocardio.com.br)

Carisi A. Polanczyk PhD³⁶ (Polanczyk CA - carisi.anne@gmail.com, 0000-0002-2447-2577)

Maria do Carmo P. Nunes PhD³⁷ (Nunes MCP - mcarmo@waymail.com.br, 0000-0001-8801-1828)

Affiliations, positions and addresses:

¹ Researcher. Vall d'Hebron University Hospital, PROSICS Barcelona. Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain. Instituto René Rachou-FIOCRUZ Minas. Av. Augusto de Lima, 1715, Belo Horizonte, Brazil.

² Associate Professor and Internal Medicine Physician. Department of Internal Medicine, Medical School; and Telehealth Center, University Hospital, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena 190 sala 246, Belo Horizonte, Brazil. Researcher. Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

³ Associate Professor and Statistician, Department of Statistics, Universidade Federal de Minas Gerais. Av. Presidente Antônio Carlos, 6627, ICEX, sala 4071, Belo Horizonte, Brazil.

⁴ Undergraduate Statistics Students, Universidade Federal de Minas Gerais. Av. Presidente Antônio Carlos, 6627, Belo Horizonte, Brazil.

⁵ Teaching and Research Coordinator, Hospital Marcio Cunha. Av. Tsunawaki Avenue, 41, Ipatinga, Brasil.

⁶ Computer scientist. Medical School, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

⁷ Nurse and Researcher. Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

⁸ Physician. Hospital UNIMED BH. Av. do Contorno, 3097, Belo Horizonte, Brazil.

⁹ Undergraduate Medical student. Hospital Metropolitanou Doutor Célio de Castro. Rua Dona Luiza, 311, Belo Horizonte, Brazil.

¹⁰ Physician. Hospital Regional Antônio Dias. R. Maj. Gote, 1231, Patos de Minas, Brazil.

¹¹ Internal Medicine Resident. Hospital Risoleta Tolentino Neves. Rua das Gabirobas, 01, Belo Horizonte, Brazil.

¹² Hospital João XXIII. Av. Professor Alfredo Balena, 400, Belo Horizonte, Brazil.

¹³ Pharmaceutical. Hospital de Clínicas de Porto Alegre. Av. Ramiro Barcellos, 2350, Porto Alegre, Brazil.

¹⁴ Coordinator of the Research Sector of Grupo Hospitalar Conceição. Professor of the Graduation Program on Evaluation and Production of Technologies for the Brazilian National Health System, Hospital Nossa Senhora da Conceição and Hospital Cristo Redentor. Av. Francisco Trein, 326, Porto Alegre, Brazil.

¹⁵ Professor and Physician. Medical School, Universidade Federal de Minas Gerais. Hospital Julia Kubitschek. Avenida Professor Alfredo Balena 190 sala 246, Belo Horizonte, Brazil.

¹⁶ Emergency and Internal Medicine Physician, Hospital Unimed BH. Av. do Contorno, 3097, Belo Horizonte, Brazil.

¹⁷ Professor and Infectious Diseases Physician. Internal Medicine Department. University Hospital, Universidade Federal de Minas Gerais. Av. Prof Alfredo Balena, 110, Belo Horizonte, Brazil.

¹⁸ Hospital Risoleta Tolentino Neves. Rua das Gabirobas, 01, Belo Horizonte, Brazil.

¹⁹ Professor. Hospital de Clínicas de Porto Alegre. Av. Ramiro Barcellos, 2350, Porto Alegre, Brazil.

²⁰ Undergraduate Medical Student. Universidade do Vale do Taquari (UNIVATES). Av. Avelino Talini, 171, Lajeado, Brazil.

²¹ Undergraduate Medical Student. Medical School, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

²² PhD Student in Business and Administration. Center for Research and Graduate Studies in Business Administration, Universidade Federal de Minas Gerais. Av. Presidente Antônio Carlos, 6627, Belo Horizonte, Brazil. Researcher. Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcellos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

²³ Hospital Nossa Senhora da Conceição. Av. Francisco Trein, 326, Porto Alegre, Brazil.

²⁴ Clinical Pharmacist - UDM Coordinator of Specialized Assistance Service. Pharmaceutical Assistance Research Center of Vale do Taquari. Av. Rio Branco, 1127, Estrela, Brazil.

²⁵ Undergraduate Medical Student. Centro Universitário de Patos de Minas. R. Maj. Gote, 808, Patos de Minas, Brazil.

²⁶ Physician and Master's Student. Medical School, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, sala 246, Belo Horizonte, Brazil.

²⁷ Physician. Hospital Eduardo de Menezes. R. Dr. Cristiano Rezende, 2213, Belo Horizonte, Brazil.

²⁸ Coordinator of the Teaching and Research Center, Hospital Metropolitan Doutor Célio de Castro. Rua Dona Luiza, 311, Belo Horizonte, Brazil.

²⁹ Undergraduate Medical Student. Pontífica Universidade Católica de Minas Gerais. Av. Dom José Gaspar, 500, Belo Horizonte, Brazil.

³⁰ Infectious Diseases Physician. Hospital Eduardo de Menezes. R. Dr. Cristiano Rezende, 2213 - Bonsucesso, Belo Horizonte. Brazil.

³¹ Hospital Nossa Senhora da Conceição. Av. Francisco Trein, 326, Porto Alegre, Brazil.

³² Physician. Hospital Bruno Born. Av. Benjamin Constant, 881, Lajeado, Brazil.

³³ Full Professor, Department of Internal Medicine, Medical School; and Telehealth Center, University Hospital, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil. Researcher. Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

³⁴ Clinical and Interventional Cardiologist. Faculty of Medicine School of Fundação Educacional do Município de Assis. Escola de Medicina da Fundação Educacional do Município de Assis / Santa Casa de Assis. Av. Getúlio Vargas, 1200, Assis, Brazil.

³⁵ Coordinator of the Hemodynamics and Interventional Cardiology Service. Hospital Balbino. R. Angélica Mota, 90, Rio de Janeiro, Brazil.

³⁶ Professor and Physician. Internal Medicine Department. Universidade Federal do Rio Grande do Sul. Coordinator of the Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

³⁷ Associate Professor. Department of Internal Medicine, Medical School; University Hospital, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

* These authors contributed equally to the work.

Correspondence to: Milena Soriano Marcolino

University Hospital, Universidade Federal de Minas Gerais
Avenida Professor Alfredo Balena, 110 Room 107. Ala Sul.
Santa Efigênia – Belo Horizonte – MG. Brazil.
CEP 30130-100

Key messages

What is already known about this subject?

- Preexisting cardiovascular disease enhances vulnerability to COVID-19.
- Co-infection with SARS-CoV-2 and *T.cruzi* can occur in patients living in areas in which both infections are epidemic.

What does this study add?

- Despite a higher frequency of chronic heart failure and atrial fibrillation, our findings do not suggest that co-infection with *T.cruzi* and SARS-CoV-2 worsens in-hospital outcomes.
- Chagas disease patients were observed to have lower C-reactive protein (CRP) levels.

How might this impact on clinical practice?

- Given the current circulation of SARS-CoV-2 at high levels and millions of *T.cruzi*-infected individuals living in Brazil, the risk for co-infections substantially increases.
- Further studies are needed to investigate why CRP levels were lower in CD patients. We hypothesized that CD patients might have a lower risk of unregulated inflammatory response to COVID-19, as they already have an active chronic inflammatory and immune response response triggered by *T.cruzi* infection.

Abstract

Objective: Chagas disease (CD) continues to be a major public health burden in Latin America, where co-infection with SARS-CoV-2 can occur. However, information on the interplay between COVID-19 and Chagas disease is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients.

Methods: Patients with COVID-19 diagnosis were selected from the Brazilian COVID-19 Registry, a prospective multicenter cohort, from March to September, 2020. CD diagnosis was based on hospital record at the time of admission. Study data were collected by trained hospital staff using Research Electronic Data Capture (REDCap) tools. Genetic matching for sex, age, hypertension, DM and hospital was performed in a 4:1 ratio.

Results: Of the 7,018 patients who had confirmed infection with SARS-CoV-2 in the registry, 31 patients with CD and 124 matched controls were included. Overall, the median age was 72 (64.-80) years-old and 44.5% were male. At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls ($p < 0.05$ for both). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). Seventy-two (46.5%) patients required admission to the intensive care unit. In-hospital management, outcomes and complications were similar between the groups.

Conclusions: In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

Key words: Chagas disease, COVID-19, prognosis

Introduction

Since the first case of coronavirus disease 19 (COVID-19) described in Brazil on February 26th, 2020, SARS-CoV 2 infection has evolved as a global pandemic. The disease has a wide spectrum of clinical manifestations, ranging from asymptomatic cases to severe pneumonia and acute respiratory distress syndrome. [1,2]

Although the great majority of symptoms are unspecified, mild, flu-like or belonging to respiratory sphere, other organs could be affected, as the cardiovascular system. COVID-19 has been associated with multiple cardiac manifestations, including cardiac arrhythmias, myocardial infarction, acute heart failure and acute fulminant myocarditis. Cardiovascular involvement has shown to be associated with increased mortality. [3,4]

Underlying comorbidities have been widely associated with a worse prognosis for COVID-19 patients, since viral infections could act as triggers for worsening of chronic diseases.[5–7] Chagas disease (CD) is a multisystemic disorder, potentially affecting, cardiovascular, digestive, and neurological systems. It is the most common cause of infectious cardiomyopathy worldwide, and it may play a role in the clinical prognosis of COVID-19 patients. [8,9] Although CD is endemic in Latin America, it has been recognized that the disease is now a worldwide concern, as the disease spread with population movements from endemic to non-endemic countries.[10] In Brazil, CD still remains a public health challenge, being one the countries with more absolute number of patients and an annual incidence rate of approximately 0.16 per 100,000 inhabitants/year.[11]

Potential interactions between COVID-19 and Chagas cardiomyopathy could be probable, because both conditions share the same immunological pathway. SARS-CoV-2 spike proteins bind to angiotensin-converting enzyme-2 (ACE-2), which is needed to invade the host cell. On the other hand, ACE2 is involved in heart function and the development of hypertension and diabetes mellitus (DM), risk factors frequently observed in patients with chronic Chagas cardiomyopathy. [12,13] Those patients could have increased levels of ACE2 because of the chronic use of ACE inhibitors and/or angiotensin receptor blockers (ARBs).

Limited information is available regarding the characteristics and outcomes of patients with CD and COVID-19. Therefore, we aim to describe the characteristics, laboratory, and imaging findings, as well as in-hospital outcomes of CD and COVID-19 coinfecting patients included in the Brazilian COVID-19 Registry.

Methods

This manuscript adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline. [14]

Study design and subjects

Patients were selected from the Brazilian COVID-19 Registry, a prospective multicenter cohort project with 37 participant hospitals in 17 cities from three Brazilian states (Minas Gerais, Pernambuco, Rio Grande do Sul, Santa Catarina, São Paulo). Details of the cohort were published elsewhere. [5]

COVID-19 diagnosis was confirmed through real time polymerase-chain reaction (RT-PCR) nasopharyngeal and oropharyngeal swab testing or anti- SARS-CoV-2 IgM detected in serological assay in serum or plasma sample, according to World Health Organization guidance. [15]

For the present study, patients with previous history of CD recorded in the database were selected. CD diagnosis were retrieved by their own hospital record or self-referred by the patient. Patients were admitted from March 1 to September 30, 2020. At the moment of the analysis 7,018 patients were introduced in the registry, 31 of those were classified as suffering from CD.

Data collection

Study data were collected by trained hospital staff or interns using Research Electronic Data Capture (REDCap) tools. [16] Medical records were reviewed to collect data on patients' demographic and clinical characteristics, including age, sex, pre-existing medical conditions and home medications; COVID-19 symptoms at hospital presentation; clinical assessment upon hospital admission, third and fifth admission days; laboratory, imaging, electrocardiographic data; inpatient medications, treatment and outcomes. Definitions were published elsewhere. [5]

Statistical analysis

Genetic matching for sex, age, hypertension, DM and hospital was performed in a 4:1 ratio (MatchIt package in R). Sample size of 132 controls was calculated

considering and expected risk ratio for mortality 2.5 in CD-group, power of 80%, alpha-error probability of 5% for a 4:1 CD/control.

Categorical data were presented as absolute numbers and proportions, and continuous variables were expressed as medians and interquartile ranges. The χ^2 and Fisher Exact test were used to compare the distribution of categorical variables, and the Wilcoxon-Mann-Whitney test for continuous variables. Results were considered statistically significant if the two-tailed P-value was < 0.05 . All statistical analysis was performed with R software (version 4.0.2).

Ethics

The study was approved by the National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived owing to the pandemic situation and the use of deidentified data, based on medical chart review only.

Results

Patient characteristics at hospital admission

From the 155 patients included in the study (Figure 1), 31 were reported as having Chagas disease, and 124 were matched controls. The median age was 72.0 (64.0-79.5) years-old and 44.5% were male. Hypertension (65.8%), DM (32.3%), chronic obstructive pulmonary disease (COPD) in (16.7%), chronic heart failure (12.9%) and atrial fibrillation (10.3%) were the most frequent comorbidities.

Patients were from 11 hospitals, with average 382 beds (ranging from 60 to 936 beds). Nine of them (81.8%) were public, 7 (63.6%) were teaching hospitals and 8 (72.7%) were reference centers for COVID-19 treatment.

When comparing CD patients with controls (Table 1), there were no significant differences in demographic and medical characteristics, except for the prevalence of chronic heart failure (8 [25.8%] vs 12 [9.7%]; $p=0.031$) and atrial fibrillation (9 [29.0%] vs 7 [5.6%]; $p < 0.001$), which were more prevalent in CD patients. Although the median number of comorbidities was higher in CD patients (3.0 [2.0, 4.0] vs. 2.0 [1.0, 3.0]), this difference did not reach statistical significance ($p=0.119$).

The median time since from symptom onset to hospital admission was 6 (8-4) days. Dyspnea and cough (dry or productive) were present in more than one half of patients. There were no differences in the clinical presentation between both groups (Table 2).

Laboratory and imaging findings are presented in Supplementary Table 1 and 2. Median C-reactive protein was lower in CD patients than the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7,167.5] mg/dL). There was no other clinically relevant difference in laboratory exams between groups.

At admission, diffuse interstitial infiltrate pattern and ground glass opacities were the most prevalent findings in the chest X-ray and chest computer tomography (CT), respectively. No significant differences were found in the frequency of abnormalities and radiological progression in both groups, except for the frequency of pleural effusion in the follow-up CT, more frequent in CD patients.

Among CD, patients 10 had an EKG performed. Of those, 4 patients had atrial fibrillation and 2 had a pacemaker rhythm, so the proportion of patients with sinus rhythm in controls were significantly higher than in CD patients (68.8% vs 40.0%, $p = 0.142$) (Table 3).

Treatment and clinical outcomes

There were no differences regarding the therapeutic strategy among both groups (Table 4), except for a trend of higher frequency of therapeutic anticoagulation in CD patients (19.3% vs. 10.5%, $p=0.206$). Twenty-four CD patients (77.4%) and 103 controls (83.0%) received corticosteroids ($p=0.448$). Dexamethasone was used by 64.5% CD patients and 66.1% controls ($p>0.999$). Macrolides were prescribed for 77.4% in CD patients and 87.1% controls ($p=0.255$); chloroquine or hydroxychloroquine in 3.2% and 4.8% ($p>0.999$). Only one patient received remdesivir.

During hospitalization, 72 (46.5%) of patients required admission to the intensive care unit, and among them 55 (35.4%) needed mechanical ventilation and 26 (16.8%) substitutive renal therapy. Overall, there were no differences in in terms of clinical evolution and outcomes (Table 5).

Discussion

We described a cohort of CD patients infected with SARS-COV-2 and admitted in hospitals belonging to a large Brazilian COVID-19 Registry project. Overall, CD patients had similar clinical characteristics and outcomes to non-CD controls, matched by age, sex, hypertension, DM and hospital, except from a higher prevalence of atrial fibrillation and chronic heart failure, and lower C-reactive protein levels.

Due to the potential cardiac involvement, and the higher procoagulant state, *T.cruzi* and SARS-COV-2 coinfection has been postulated as condition for myocardial damage, depression of ventricular function, increased arrhythmogenic state, thromboembolism risk, and ultimately a worst prognosis.[17–19] However, it was only a hypothesis and no previous study has tested it using patient data. Despite the limited number of patients with CD (31) our study refuted did not confirm the hypothesis. We did not find any significant difference or even a trend of worse clinical outcomes in CD patients, even with a higher frequency of atrial fibrillation and heart failure in the CD group.

Current data demonstrates that SARS-CoV-2 infection induces immune dysfunction, widespread endothelial injury, complement-associated coagulopathy and systemic microangiopathy. [20] By the other hand, *T. cruzi* infection is associated with an upregulated procoagulant activity in plasma. Therefore, it could be expected a greater risk of thromboembolic manifestations. In our cohort the overall thrombosis event was 4.5% (7 out of 155), all of them were in the control group. Noteworthy that, the great majority of patients (91%) were treated with oral anticoagulants because its underlying disease or received any kind of prophylactic heparin when admitted to the hospital, as recommended by national and international guidelines for the management of in-hospital COVID-19 patients. [21,22]

The lower median C-reactive level in CD patients was an unexpected finding. We hypothesize that CD patients, as they already have an active chronic inflammatory and immune response response triggered by *T.cruzi* infection, might have a lower risk of unregulated inflammatory response to COVID-19. [23]Therefore, what could have been a factor for worse prognosis, due to a higher frequency of associated heart failure and atrial fibrillation and the CD itself, could be equilibrated by a controlled inflammatory response. This is only a hypothesis, that merits consideration for future studies. If proved correct, it may add to the knowledge of understating how to prevent the unregulated inflammatory response in COVID-19.

It is also interesting to discuss the influence that the use of anticoagulants in full doses may have had on the outcomes of patients with CD and COVID-19. The higher prevalence of atrial fibrillation in those patients may had led to a higher frequency of use of therapeutic dosage anticoagulants (19.3% vs. 10.5%), which did not reach statistical significance due to the sample size. The best strategy to be used - prophylactic or therapeutic heparin doses - in patients with moderate to severe COVID-19 is not yet

defined, and it has been hypothesized that therapeutic anticoagulation (full dose heparin) is associated with decreased in-hospital mortality in patients with moderate COVID-19, but not in patients with severe COVID-19.

It is known the effect of immunosuppressant drugs and the risk of reactivation of CD. In the case of corticosteroids, immunosuppressive doses have not been associated with higher rates of reactivation of CD, although is controversial due to the lack of supporting evidence. [24,25] Tocilizumab, a cytokine inhibitor (recombinant humanized monoclonal antibody with an antagonist effect on the IL-6 receptor), combined with another immunosuppressant agents have been suggested to be associated with the reactivation of latent infections, including parasites.

Two published case reports of Strongyloides Hyperinfection Syndrome in COVID-19 patients immunosuppressed with dexamethasone and tocilizumab, have been recently published. [26,27] To date, no cases of CD reactivation have been published, but at least, there is a concern that COVID-19 disease therapeutics could potentially trigger reactivation of CD. This merits further investigation and until definitive evidence is published, it should be a cause of concern in decision making, when prescribing immunosuppressors in these patients.

The fact that the majority of CD patients were admitted to public hospitals (81.8%) is an indicator that CD disproportionately affects people from lower income background. In a previous multivariate analysis, we demonstrated that despite being admitted to public hospitals patients do not have worse prognosis than patients admitted to private ones.[5]

This study has limitations. In addition to the retrospective design, subject to the drawbacks of a patient records review, the number of CD was low. However, it is the largest series published to date. Due to the pragmatic study design, laboratory and imaging tests were performed at the discretion of the treating physician. Despite the limited representativity of radiologic, tomographic and electrocardiographic analysis, no patient performed echocardiogram during hospital admission.

Conclusions

Although coinfection by *Trypanosoma cruzi* and SARS-COV-2 may pose a risk of complications and therefore a worse prognosis, in our series we did not find significant differences in terms of clinical presentation and outcomes of patients with CD compared to controls, despite a higher frequency of chronic heart failure and atrial

fibrillation at baseline. We observed lower C-reactive protein levels in CD when compared to controls, and this merits further investigation.

Acknowledgments

We would like to thank the hospitals which are part of this collaboration, for supporting this Project. Specifically for this analysis, we thank the hospitals: Hospital Bruno Born; Hospital das Clínicas da UFMG; Hospital de Clínicas de Porto Alegre; Hospital Eduardo de Menezes; Hospital João XXIII; Hospital Julia Kubitschek; Hospital Metropolitano Dr. Célio de Castro; Hospital Nossa Senhora da Conceição; Hospital Regional Antônio Dias; Hospital Risoleta Tolentino Neves; Hospital Unimed-BH.

We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection.

Funding

This study was supported in part by Minas Gerais State Agency for Research and Development (*Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG*) [grant number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (*Instituto de Avaliação de Tecnologias em Saúde – IATS*)/ National Council for Scientific and Technological Development (*Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq*) [grant number 465518/2014-1], and CAPES Foundation (*Coordenação de Aperfeiçoamento de Pessoal de Nível Superior*) [grant number 88887.507149/2020-00].

Role of the funder/sponsor

The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and decision to submit it for publication. IM, MSM and MP had full access to all the data in the study and had responsibility for the decision to submit for publication.

Conflicts of interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability statement

Data are available upon reasonable request.

Transparency declaration

The lead authors (MSM, IM and MCP) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

Author contribution

Substantial contributions to the conception or design of the work: MSM, IMR, IJRO, MCP, MCPN.

Substantial contributions to the acquisition, analysis, or interpretation of data for the work: IMR, MSM, LMO, MCP, RTS, MHCG, IJRO, LSM, RLRC, AGSN, ANRMB, ANBAS, AACM, BLF, CAC, FDAR, FA, FAB, GFN, HD, HCG, JCA, LBM, LBZ, LFA, LK, LCC, LEAS, MASC, MAPF, NCSS, NRO, SCF, SJTSL, VBS, VRBC, YCRFABM, RM, MCPN

Drafted the work: IMR, MSM, MCP, MCPN.

Revised the manuscript critically for important intellectual content: all authors.

Final approval of the version to be published: all authors.

Drafted the work: IM, MSM, MCP, MCPN.

Revised the manuscript critically for important intellectual content: all authors.

Final approval of the version to be published: all authors.

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: MSM and MCP.

References

- 1 Guan W-J, Ni Z-Y, Hu Y, *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;**382**:1708–20. doi:10.1056/NEJMoa2002032
- 2 Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, *et al.* Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis* 2020;**34**:101623. doi:10.1016/j.tmaid.2020.101623
- 3 Madjid M, Safavi-Naeini P, Solomon SD, *et al.* Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiol* 2020;**5**:831–40. doi:10.1001/jamacardio.2020.1286
- 4 Zheng Y-Y, Ma Y-T, Zhang J-Y, *et al.* COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020;**17**:259–60. doi:10.1038/s41569-020-0360-5
- 5 Marcolino MS, Ziegelmann PK, Souza-Silva MVR, *et al.* Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: results from the Brazilian COVID-19 Registry. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis* Published Online First: 11 January 2021. doi:10.1016/j.ijid.2021.01.019
- 6 Marcolino MS, Pires MC, Ramos LEF, *et al.* ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores. *medRxiv* 2021;:2021.02.01.21250306. doi:10.1101/2021.02.01.21250306
- 7 Knight SR, Ho A, Pius R, *et al.* Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* 2020;**370**:m3339. doi:10.1136/bmj.m3339
- 8 Andrade JP de, Marin-Neto JA, Paola AAV de, *et al.* [I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy]. *Arq Bras Cardiol* 2011;**97**:1–48.
- 9 Pérez-Molina JA, Molina I. Chagas disease. *Lancet Lond Engl* 2018;**391**:82–94. doi:10.1016/S0140-6736(17)31612-4
- 10 Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. *Nature* 2010;**465**:S6-7. doi:10.1038/nature09221
- 11 Chagas disease in Latin America: an epidemiological update based on 2010 estimates. *Relevé Épidémiologique Hebd Sect Hygiène Secrétariat Société Nations Wkly Epidemiol Rec Health Sect Secr Leag Nations* 2015;**90**:33–43.
- 12 Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *J Antimicrob Chemother* Published Online First: 20 March 2020. doi:10.1093/jac/dkaa114
- 13 Zaidel EJ, Forsyth CJ, Novick G, *et al.* COVID-19: Implications for People with Chagas Disease. *Glob Heart*; **15**. doi:10.5334/gh.891

- 14 von Elm E, Altman DG, Egger M, *et al.* Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;**335**:806–8. doi:10.1136/bmj.39335.541782.AD
- 15 WHO-2019-nCoV-laboratory-2020.6-por.pdf. <https://apps.who.int/iris/bitstream/handle/10665/334254/WHO-2019-nCoV-laboratory-2020.6-por.pdf> (accessed 21 Mar 2021).
- 16 Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap)-- a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;**42**:377–81. doi:10.1016/j.jbi.2008.08.010
- 17 Guzik TJ, Mohiddin SA, Dimarco A, *et al.* COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res* Published Online First: 30 April 2020. doi:10.1093/cvr/cvaa106
- 18 Siripanthong B, Nazarian S, Muser D, *et al.* Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. *Heart Rhythm* 2020;**17**:1463–71. doi:10.1016/j.hrthm.2020.05.001
- 19 Pinazo M-J, Posada E de J, Izquierdo L, *et al.* Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. *PLoS Negl Trop Dis* 2016;**10**:e0004269. doi:10.1371/journal.pntd.0004269
- 20 Perico L, Benigni A, Casiraghi F, *et al.* Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. *Nat Rev Nephrol* 2020;:1–19. doi:10.1038/s41581-020-00357-4
- 21 Falavigna M, Colpani V, Stein C, *et al.* Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. *Rev Bras Ter Intensiva* 2020;**32**. doi:10.5935/0103-507X.20200039
- 22 ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. <https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance>, <https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance> (accessed 21 Mar 2021).
- 23 Acevedo GR, Girard MC, Gómez KA. The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease. *Front Immunol* 2018;**9**. doi:10.3389/fimmu.2018.01929
- 24 Salvador F, Sánchez-Montalvá A, Valerio L, *et al.* Immunosuppression and Chagas disease; experience from a non-endemic country. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2015;**21**:854–60. doi:10.1016/j.cmi.2015.05.033

- 25 Pinazo M-J, Espinosa G, Cortes-Lletget C, *et al.* Immunosuppression and Chagas Disease: A Management Challenge. *PLOS Negl Trop Dis* 2013;**7**:e1965.
doi:10.1371/journal.pntd.0001965
- 26 Marchese V, Crosato V, Gulletta M, *et al.* Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. *Infection* 2020;:1–4. doi:10.1007/s15010-020-01522-4
- 27 Lier AJ, Tuan JJ, Davis MW, *et al.* Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19. *Am J Trop Med Hyg* 2020;**103**:1590–2.
doi:10.4269/ajtmh.20-0699

Tables

Table 1. Demographic characteristics and medical history data of the study population at baseline

	CD patients (n=31)	Controls (n=124)	p-value
Age* (years)	74.0 (64.5, 79.0)	72.0 (64.0, 80.0)	0.856
Male sex*	14 (45.2%)	55 (44.4%)	>0.999
Comorbidities**			
Total number			0.461
0	3 (9.7%)	11 (8.9%)	
1	3 (9.7%)	27 (21.8%)	
2	9 (29.0%)	39 (31.5%)	
3	7 (22.6%)	26 (21.0%)	
4	6 (19.4%)	16 (12.9%)	
≥ 5	3 (9.7%)	5 (4.0%)	
<i>Cardiovascular diseases</i>			
Hypertension*	20 (64.5%)	82 (66.1%)	>0.999
Ischemic cardiopathy	1 (3.2%)	6 (4.8%)	>0.999
Chronic heart failure	8 (25.8%)	12 (9.7%)	0.031
Atrial fibrillation/flutter	9 (29.0%)	7 (5.6%)	<0.001
Stroke	2 (6.5%)	8 (6.5%)	>0.999
Pacemaker	1 (3.2%)	0 (0.0%)	0.200
<i>Respiratory diseases</i>			
Asthma	1 (3.2%)	9 (7.3%)	0.688
COPD	8 (25.8%)	18 (14.5%)	0.216
<i>Metabolic diseases</i>			
Diabetes mellitus*	10 (32.3%)	40 (32.3%)	>0.999
Obesity (BMI>30)	1 (3.2%)	10 (8.1%)	0.695

<i>Other conditions</i>			
Cirrhosis	0 (0.0%)	2 (1.6%)	>0.999
Psychiatric condition	1 (3.2%)	9 (7.3%)	0.688
Chronic renal disease	0 (0.0%)	3 (2.4%)	>0.999
Dyslipidemia	0 (0.0%)	1 (0.8%)	>0.999
HIV	0 (0.0%)	2 (1.6%)	>0.999
Neoplasia	3 (9.7%)	8 (6.5%)	0.461
Transplantation	1 (3.2%)	3 (2.4%)	>0.999
Dementia	0 (0.0%)	1 (0.8%)	>0.999
Epilepsy	0 (0.0%)	0 (0.0%)	-
Toxic habits			
Alcohol	1 (3.2%)	6 (4.8%)	>0.999
Tobacco (active or former)	7 (22.6%)	35 (28.2%)	0.684

Numbers are presented as medians (P25-P75) or counts (percentages).

BMI: body mass index; CD: Chagas disease; COPD: chronic obstructive pulmonary disease.

* Controls were paired for age, sex, hospital, hypertension and diabetes.

** This variable does not include Chagas disease.

Table 2. Clinical characteristics of the study population at baseline

	CD patients (n=31)		Controls (n=124)		p-value
	Frequency (%) or median (IQR)	Valid cases	Frequency (%) or median (IQR)	Valid cases	
Symptoms					
Time from symptom onset	5.0 (3.0, 7.8)	30	6.0 (3.8, 9.2)	124	0.392
Adynamic	10 (32.3%)	31	37 (29.8%)	124	0.965
Ageusia	4 (12.9%)	31	7 (5.6%)	124	0.232
Anosmia	5 (16.1%)	31	10 (8.1%)	124	0.183
Headache	7 (22.6%)	31	22 (17.7%)	124	0.719
Rhinorrhea	4 (12.9%)	31	20 (16.1%)	124	0.786
Diarrhea	3 (9.7%)	31	18 (14.5%)	124	0.573
Dyspnea	19 (61.3%)	31	73 (58.9%)	124	0.967
Odynophagia	14 (45.2%)	31	64 (51.6%)	124	0.659
Fever	4 (12.9%)	31	17 (13.7%)	124	>0.999
Hyporexia	1 (3.2%)	31	5 (4.0%)	124	>0.999
Neurological manifestations	6 (19.4%)	31	34 (27.4%)	124	0.491
Myalgia	2 (6.5%)	31	19 (15.3%)	124	0.252
Nausea/vomiting	7 (22.6%)	31	21 (16.9%)	124	0.639
Productive cough	18 (58.1%)	31	65 (52.4%)	124	0.717
Dry cough	1 (3.2%)	31	1 (0.8%)	124	0.361
Clinical assessment					
Glasgow <15	6 (19.4%)	31	24 (19.4%)	124	>0.999
HR	80.0 (72.0, 86.8)	30	84.0 (77.0, 96.0)	121	0.060
HR ≥ 100 bpm	4 (12.9%)	31	28 (22.6%)	124	0.346
RR	22.0 (18.5, 26.0)	27	22.0 (18.0, 25.0)	115	0.748
RR ≥ 24 irpm	16 (51.6%)	31	56 (45.2%)	124	0.658
Sat O ₂	94.0 (91.0, 96.0)	29	94.0 (90.0, 96.0)	123	0.712
Sat O ₂ < 90%	7 (22.6%)	31	28 (22.6%)	124	>0.999
SF ratio	402.4 (300.0, 440.5)	28	395.8 (240.0, 438.1)	123	0.316
Invasive ventilation	3 (9.7%)	31	13 (10.5%)	124	>0.999

SBP \leq 100 mmHg	1 (3.2%)	31	11 (8.9%)	124	0.462
Inotropic drugs	12 (38.7%)	31	45 (36.3%)	124	0.967

CD: Chagas disease; HR: hear rate; IQR: interquartile range; RR: respiratory rate; SF ratio: Sat O₂/FiO₂; valid cases: non missing cases.

Table 3. Electrocardiographic characteristics of the study population at baseline and new abnormalities at follow-up

	CD patients (n=31)	Control patients (n=124)	p-value
ECG at admission	10 (32.3%)	32 (26.0%)	0.637
Sinus rhythm	4 (40.0%)	22 (68.8%)	0.142
Atrial fibrillation or flutter	4 (40.0%)	7 (21.9%)	0.410
Pacemaker	2 (20.0%)	1 (3.1%)	0.136
Right bundle branch block	1 (10.0%)	4 (12.5%)	>0.999
Left bundle branch block	2 (20.0%)	1 (3.1%)	0.136
Left ventricular hemiblock	0 (0.0%)	0 (0.0%)	
New electrocardiographic abnormalities*	N*=4 (12.9%)	N*=15 (12.3%)	>0.999
Rhythm			
Atrial fibrillation or flutter	4 (100.0%)	6 (40.0%)	0.087
Pacemaker	1 (25.0%)	0 (0.0%)	0.211
Multifocal atrial rhythm	0 (0.0%)	1 (6.7%)	>0.999
Supraventricular tachycardia	0 (0.0%)	1 (6.7%)	>0.999
Monomorphic ventricular tachycardia	0 (0.0%)	3 (20.0%)	>0.999
Polymorphic ventricular tachycardia	0 (0.0%)	1 (6.7%)	>0.999
No new rhythm abnormalities	0 (0.0%)	4 (26.7%)	0.530
New long QTc interval	1 (25.0%)	2 (13.3%)	0.530
None	2 (50.0%)	4 (26.7%)	0.557

* New electrocardiographic abnormalities through in-hospital follow-up, and number of patients in which this outcome was assessed.

Table 4. Medications

	CD patients (n=31)	Controls (n=124)	p-value
Azithromycin	23 (74.2%)	91 (73.4%)	>0.999
Clarithromycin	1 (3.2%)	17 (13.7%)	0.126
Chloroquine	0 (0.0%)	1 (0.8%)	>0.999
Hydroxychloroquine	1 (3.2%)	5 (4.0%)	>0.999
Remdesivir	0 (0.0%)	2 (1.6%)	>0.999
Anticoagulation			
Profilatic			
Low-molecular-weight	16 (51.6%)	65 (52.4%)	>0.999
Non-fractionated	11 (35.5%)	58 (46.8%)	0.353
Fondaparinux	0 (0.0%)	1 (0.8%)	>0.999
Therapeutic	0 (0.0%)	1 (0.8%)	>0.999
Low-molecular-weight	5 (16.1%)	8 (6.5%)	0.138
Non-fractionated	1 (3.2%)	5 (4.0%)	>0.999

Table 5. Clinical outcomes

	CD patients (n=31)		Control patients (n=124)		p-value
	Frequency (%) or median (IQR)	Valid cases	Frequency (%) or median (IQR)	Valid cases	
Length of stay	8.0 (4.5, 13.5)	31	10.0 (7.0, 17.0)	124	0.220
Admission to ICU	16 (51.6%)	31	56 (45.2%)	124	0.658
Time from admission to ICU (days)	1.0 (0.0, 2.0)	16	0.5 (0.0, 2.0)	56	0.891
Days in ICU	6.0 (2.0, 11.2)	16	7.5 (4.0, 14.0)	56	0.352
Thromboembolic events	0 (0.0%)	31	7 (5.6%)	124	0.346
Mechanical ventilation	10 (32.3%)	31	45 (36.3%)	124	0.834
Acute kidney injury	9 (37.5%)	24	45 (41.7%)	108	0.884
RRT	5 (16.1%)	31	21 (16.9%)	124	>0.999
Sepsis	6 (19.4%)	31	24 (19.4%)	124	>0.999
Nosocomial infection	3 (9.7%)	31	24 (19.4%)	124	0.314
Acute heart failure	2 (6.5%)	31	5 (4.0%)	124	0.628
Acute respiratory distress	9 (29.0%)	31	44 (35.5%)	124	0.641
Death	10 (32.3%)	31	38 (30.6%)	124	>0.999

ICU: intensive care unit; IQR: interquartile range; RRT: renal replacement therapy

Figure




Figure 1. Flowchart of COVID-19 patients included in the study

Table S1. Laboratory parameters of the study population at baseline

	CD patients (n=31)		Controls (n=124)		p-value
	Frequency (%) or median (IQR)	Valid cases	Frequency (%) or median (IQR)	Valid cases	
Hemoglobin (g/dL)	12.8 (12.1, 14.1)	28	12.9 (11.8, 14.0)	120	0.849
White blood cell count (x10 ⁹ /L)	6.3 (4.7, 8.0)	28	7.0 (5.1, 10.0)	120	0.205
Neutrophils (x10 ⁹ /L)	4,142.5 (3,287.5, 6,102.2)	28	5,548.5 (3,528.8, 7,597.5)	118	0.154
Lymphocytes (x10 ⁹ /L)	960.0 (609.8, 1,443.8)	28	1,001.0 (688.2, 1,291.5)	116	0.824
Platelets (x10 ⁹ /L)	221.5 (147.3, 319.8)	28	194.2 (138.3, 272.5)	119	0.186
Albumin (g/dL)	3.3 (2.9, 3.7)	13	3.2 (2.9, 3.6)	50	0.792
AST (U/L)	45.0 (28.8, 50.5)	20	46.0 (33.0, 69.0)	79	0.351
ALT (U/L)	26.5 (14.0, 38.2)	20	30.0 (21.8, 47.0)	80	0.154
Calcium (mmol/L)	1.1 (1.0, 1.2)	10	1.1 (1.1, 1.1)	39	0.302
Creatinine (mg/dL)	1.0 (0.9, 1.2)	27	0.9 (0.7, 1.3)	117	0.546
CPK (U/L)	87.5 (64.0, 183.0)	10	107.0 (47.0, 306.0)	41	0.553
C-reactive protein (mg/dL)	55.5 (35.7, 85.0)	28	94.3 (50.7, 167.5)	115	0.013
D-dimer (ng/mL)	1.9 (1.1, 600.0)	17	4.0 (1.9, 1,765.0)	68	0.106
LDH (U/L)	435.0 (311.0, 471.5)	19	381.5 (285.0, 515.2)	76	0.930
Lactate (mmol/L)		31		123	0.863
Potassium (mmol/L)	4.3 (3.8, 4.7)	27	4.3 (3.9, 4.7)	116	0.782
aPTT (seconds)	1.1 (1.0, 1.4)	22	1.0 (0.9, 1.1)	87	0.004
INR	1.2 (1.1, 1.6)	23	1.1 (1.0, 1.2)	89	0.018
Sodium (mmol/L)	137.0 (133.9, 139.8)	26	137.0 (133.6, 141.0)	115	0.856
Total bilirubin (mg/dL)	0.4 (0.3, 0.6)	18	0.5 (0.3, 0.7)	83	0.866
Troponin (ng/mL)	0.6 (0.5, 3.5)	9	0.6 (0.1, 1.0)	40	0.366
Urea (mg/dL)	40.5 (32.8, 59.8)	28	42.0 (31.0, 67.2)	118	0.673

Table S2. Radiological characteristics of the study population at baseline

	CD patients (n=31)	Controls (n=124)	p-value
Chest X-ray at admission	19 (61.3%)	91 (73.4%)	0.269
Normal	3 (15.8%)	19 (20.9%)	0.760
Atelectasis	0 (0.0%)	2 (2.2%)	>0.999
Consolidation	6 (31.6%)	15 (16.5%)	0.195
Diffuse interstitial infiltrate	9 (47.4%)	52 (57.1%)	0.599
Focal interstitial infiltrate	1 (5.3%)	6 (6.6%)	>0.999
Bilateral ground glass opacity	6 (31.6%)	17 (18.7%)	0.223
Chest X-ray at follow up	11 (35.5%)	58 (46.8%)	0.353
Normal	3 (27.3%)	9 (15.5%)	0.390
Atelectasis	0 (0.0%)	2 (3.4%)	>0.999
Consolidation	2 (18.2%)	17 (29.3%)	0.715
Diffuse interstitial infiltrate	5 (45.5%)	33 (56.9%)	0.525
Focal interstitial infiltrate	0 (0.0%)	4 (6.9%)	>0.999
Bilateral ground glass opacity	6 (54.5%)	14 (24.1%)	0.067
Radiological progression	3 (27.3%)	11 (19.0%)	0.683
Chest CT at admission	8 (25.8%)	48 (38.7%)	0.259
Normal	1 (12.5%)	3 (6.2%)	0.470
Atelectasis	2 (25.0%)	3 (6.2%)	0.144
Consolidation	2 (25.0%)	9 (18.8%)	0.649
Pleural effusion	0 (0.0%)	2 (4.2%)	>0.999
Bilateral ground glass opacity	6 (75.0%)	40 (83.3%)	0.623
Peripheral ground glass opacity	5 (62.5%)	25 (52.1%)	0.712
Crazy-paving pattern	0 (0.0%)	6 (12.5%)	0.578
Chest CT at follow up	5 (16.1%)	31 (25.0%)	0.419
Normal	0 (0.0%)	5 (16.1%)	>0.999
Atelectasis	1 (20.0%)	2 (6.5%)	0.370
Consolidation	0 (0.0%)	7 (22.6%)	0.559
Pleural effusion	3 (60.0%)	2 (6.5%)	0.013
Unilateral ground glass opacity	0 (0.0%)	2 (6.5%)	>0.999
Bilateral ground glass opacity	3 (60.0%)	19 (61.3%)	>0.999

Peripheral ground glass opacity	3 (60.0%)	19 (61.3%)	>0.999
Crazy-paving pattern	2 (40.0%)	6 (19.4%)	0.305
Progression*	5 (100.0%)	30 (96.8%)	>0.999

* Normal at admission and abnormal at follow-up

CT: computer tomography.

